Skip to main content
main-content

GLP-1 receptor agonists


Browse the latest news, expert commentary, and educational content on the GLP-1 receptor agonist medication class.


Highlights

05-06-2021 | Semaglutide | News

FDA approves higher semaglutide dose for obesity

Click through to read more on this announcement

19-05-2021 | Semaglutide | News

Semaglutide boosts weight loss of minimally invasive gastric procedure

Giving semaglutide to people undergoing minimally invasive endoscopic sleeve gastroplasty may bring weight loss closer to that induced by bariatric surgery, shows research.

04-05-2021 | Obesity | News

Cagrilintide, semaglutide combination warrants further investigation for weight loss

Phase 1 trial results published in The Lancet suggest that combination treatment with the long-acting amylin analog cagrilintide plus high-dose semaglutide is well tolerated and may be a feasible treatment option for obesity.

Semaglutide for weight loss: The STEP and SELECT trials

Get the latest results and insights from the researchers.

More on GLP-1 receptor agonists

Stay informed with Medicine Matters

Get the latest developments in diabetes delivered straight to your inbox

Image Credits